Clinical trial NCT05019066: Oral Herbal Combination Formulation and Hair Growth in Women
Official title: The Effect of an Oral Herbal Combination Formulation on Hair Growth in Women With Self-perceived Hair Loss
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hair Loss
Hair Thinning
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2021-08-24
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this research is to test the effects of an herbal combination formulation on hair growth in women with self-perceived hair loss.The information from this study may help to better understand how certain herbal supplements can affect hair growth. This may lead to better understanding of the hair, hair loss and help develop naturally-based treatment regimens in the future.


Eligibility criteria: Inclusion Criteria:

* Age 18 and above
* Subject must be able to read and comprehend study procedures and consent forms.
* Women with self-perceived hair loss as confirmed by the investigator.
* Willing to maintain the same hairstyle, hair color, hair length and hair regimen throughout the study period. Subjects with color-treated hair will have the color treatment performed at the same time interval prior to each visit (if the color treatment was done 1 week prior to Visit 1, it should be repeated 1 week prior to Visit 2).
* Willing to keep diet and exercise routine consistent throughout study

Exclusion Criteria:

* Subjects should be generally healthy and have no smoking history in the past one year.
* Subjects must have no history of diabetes, metabolic syndrome, HIV, immune deficiency, autoimmune disease known cardiovascular disease, malignancy, kidney disease, or chronic steroid use.
* Women who are pregnant, planning to become pregnant or breastfeeding
* Those who are unable to discontinue medicated shampoos or topical scalp medications for two weeks prior to and during the study.
* Those who are unable to discontinue supplements containing Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa for one month prior to starting the study
* Those who have a known allergy to Eclipta alba, Emblica officinalis, Centella asiatica or Hibiscus sabdariffa
* Use of hair regrowth products in the previous 6 months
* Using or planned use of non-breathable wigs
* Those with a history of hair transplantation procedure
* Presence of other dermatological disorders causing alopecia
* Chemotherapy, radiation therapy or laser therapy (of scalp) in the last 6 months
* Light therapy in the past 3 months
* Participants using hormonal birth control unless on a stable / unchanged regimen for at least 3 months.
* Systemic treatment during the last 3 months before study inclusion that could interfere with the study medications (ie, minoxidil, corticosteroids, Aminexil, topical estrogens, ketoconazole, beta blocker, cimetidine, diazoxide, isotretinoin or vitamin A intake \>10,000 IU/d)
* Use of ocular prostaglandins for less than 4 months before first study visit
* Those that are prisoners or cognitively impaired

Primary outcomes:
measure: Scalp photography Microscopic evaluation of hair Trichometry using the HairCheck© device
timeFrame: 24 weeks
Secondary outcomes:
measure: Global Hair Growth and Global Hair Quality Assessment by investigator Hair Loss Subjective Questionnaire Symptom questionnaire
timeFrame: 24-weeks
Other outcomes:
Locations:
Study officials:
References: